Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer

May 3, 2022

Brings in-depth R&D expertise in oncology, including ADCs, targeted radiotherapies, immunooncology and small moleculesAdcendo building a world class team of experienced biotech & pharma executives and renowned leaders in the ADC field Copenhagen, Denmark, May...

Adcendo Appoints Michael Pehl as Chief Executive Officer

Jul 6, 2021

Experienced Industry Leader with successful Oncology, Immunotherapy & ADC Development Track Record Adcendo, a biotech company developing innovative antibody-drug conjugates (ADCs) for the treatment of underserved cancers, announces today the appointment of Michael...

Adcendo Series A Press Release

Apr 29, 2021

Adcendo raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers Financing led by Novo Seeds and Ysios Capital is largest Series A for a Danish biotech companyPlans to build a pipeline of ADCs directed at novel...